Oleksii Fedorenko / shutterstock.com
The US District Court for the District Court of Delaware has ruled in favour of Sweden-based pharmaceutical company Orexo in a patent battle against Actavis over Zubsolv (buprenorphine and naloxone).
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Orexo, Actavis, patent, Zubsolv, ANDA, US District Court for the District Court of Delaware, generic
